STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal

Reuters12-16

STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal

STAAR Surgical Company's board has received a recommendation from Institutional Shareholder Services (ISS) to approve the merger with Alcon. ISS noted that the improved terms of the agreement and increasing downside risks to STAAR as a standalone company now favor the transaction. The company has been facing financial challenges, including declining net sales since 2023 due to heavy exposure to the Chinese market, heightened competition, a limited product range, and difficulty expanding beyond high myopia patients. Recent supplemental proxy materials have outlined that China procedure volumes, while initially positive, softened in the second quarter of 2025 and showed no improvement thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215265033) on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591262079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591262079","market":"fut","top_or_hot":-1,"title":"STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical Company</a>'s board has received a recommendation from Institutional Shareholder Services (ISS) to approve the merger with Alcon. ISS noted that the improved terms of the agreement and increasing downside risks to STAAR as a standalone company now favor the transaction. The company has been facing financial challenges, including declining net sales since 2023 due to heavy exposure to the Chinese market, heightened competition, a limited product range, and difficulty expanding beyond high myopia patients. Recent supplemental proxy materials have outlined that China procedure volumes, while initially positive, softened in the second quarter of 2025 and showed no improvement thereafter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215265033) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 07:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical Company</a>'s board has received a recommendation from Institutional Shareholder Services (ISS) to approve the merger with Alcon. ISS noted that the improved terms of the agreement and increasing downside risks to STAAR as a standalone company now favor the transaction. The company has been facing financial challenges, including declining net sales since 2023 due to heavy exposure to the Chinese market, heightened competition, a limited product range, and difficulty expanding beyond high myopia patients. Recent supplemental proxy materials have outlined that China procedure volumes, while initially positive, softened in the second quarter of 2025 and showed no improvement thereafter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215265033) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLc2TYsn:1","article_id":"2591262079","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591262079","pubTimestamp":1765841716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"STAAR Surgical Company's board has received a recommendation from Institutional Shareholder Services  to approve the merger with Alcon. ISS noted that the improved terms of the agreement and increasing downside risks to STAAR as a standalone company now favor the transaction. The company has been facing financial challenges, including declining net sales since 2023 due to heavy exposure to the Chinese market, heightened competition, a limited product range, and difficulty expanding beyond high myopia patients. Recent supplemental proxy materials have outlined that China procedure volumes, while initially positive, softened in the second quarter of 2025 and showed no improvement thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","BK4548":"巴美列捷福持仓","STAA":"STAAR Surgical Company"},"translate_title":"STAAR股东敦促批准每股30.75美元的爱尔康交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":0.9},"content_text":"STAAR Shareholders Urged to Approve $30.75-Per-Share Alcon Deal\n    \n\nSTAAR Surgical Company's board has received a recommendation from Institutional Shareholder Services (ISS) to approve the merger with Alcon. ISS noted that the improved terms of the agreement and increasing downside risks to STAAR as a standalone company now favor the transaction. The company has been facing financial challenges, including declining net sales since 2023 due to heavy exposure to the Chinese market, heightened competition, a limited product range, and difficulty expanding beyond high myopia patients. Recent supplemental proxy materials have outlined that China procedure volumes, while initially positive, softened in the second quarter of 2025 and showed no improvement thereafter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215265033) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591262079","isCrawlerRequest":true}